Hypoparathyroidism Epidemiology Forecast 2025-2034

Hypoparathyroidism is a rare condition characterized by the low levels of parathyroid hormone in the blood. It occurs when one or more parathyroid glands in the body become underactive. The prevalence of chronic hypoparathyroidism is estimated to be 6.4-37 per 100,000 individuals.

Hypoparathyroidism Epidemiology Forecast Report Coverage

The “Hypoparathyroidism Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hypoparathyroidism. It projects the future incidence and prevalence rates of hypoparathyroidism across various populations. The study covers age and type as major determinants of the hypoparathyroidism-affected population. The report highlights patterns in the prevalence of hypoparathyroidism over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Hypoparathyroidism in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Hypoparathyroidism: Disease Overview

Hypoparathyroidism is a rare endocrine condition caused by parathyroid hormone deficiency as a result of parathyroid gland dysfunction. In chronic cases, increased serum phosphorus, low serum calcium, and abnormally low or reduced serum parathyroid hormone are observed. The low levels of calcium in the blood can often cause cramping or twitching muscles in some patients. Both adults and children can be affected by hypoparathyroidism. However, adults are more likely to develop this endocrine abnormality from accidental damage to their parathyroid glands during thyroid or neck surgery.

Hypoparathyroidism: Treatment Overview

Treatment for hypoparathyroidism is primarily focused on minimizing symptoms and ensuring the appropriate amount of calcium and minerals is present in the patient’s body. Calcium carbonate and vitamin D supplements are commonly taken for the treatment of hypoparathyroidism. Phosphate binders such as aluminum hydroxide or sevelamer help in reducing high levels of phosphate, especially in chronic cases. If supplements are not proving to be sufficient, patients are often advised to take parathyroid hormone injections.

Epidemiology

The hypoparathyroidism epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for hypoparathyroidism by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hypoparathyroidism and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per a study published in the Journal of Bone and Mineral Research (2022), the prevalence of hypoparathyroidism is 6.4 to 37 per 100,000 person-years in the United States, with thyroidectomy or head and neck surgery complications contributing to 75% of the cases.
• A recent survey in Japan revealed the prevalence of hypoparathyroidism and idiopathic hypoparathyroidism to be 3.4 cases and 7.2 cases per million people, respectively, in the country.
• The incidence of hypoparathyroidism is estimated to be 0.8-2.3/100,000 per year, according to an article published in the Journal of Bone and Mineral Research (2022).
• Around 10% of hypoparathyroidism cases are represented by genetic causes, with DiGeorge syndrome (60%) reported as the most common genetic cause.

Country-wise Hypoparathyroidism Epidemiology

The hypoparathyroidism epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hypoparathyroidism differs between countries owing to factors such as genetic diversity across populations, the prevalence of thyroid and parathyroid surgeries, and variations in healthcare infrastructure and diagnostic capabilities. Countries with rare disease registries and robust research programs tend to have more accurate reporting of cases. In the United States, hypoparathyroidism is estimated to affect fewer than 200,000 individuals.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hypoparathyroidism based on several factors.
• Hypoparathyroidism Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, and the unmet needs of hypoparathyroidism are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hypoparathyroidism epidemiology in the 8 major markets?
• What will be the total number of patients with hypoparathyroidism across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hypoparathyroidism in the 8 major markets in the historical period?
• Which country will have the highest number of hypoparathyroidism patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hypoparathyroidism during the forecast period of 2025-2034?
• What are the currently available treatments for hypoparathyroidism?
• What are the disease risks, signs, symptoms, and unmet needs of hypoparathyroidism?

This product will be delivered within 3-5 business days.